The New England journal of medicine
The New England journal of medicine
Audio Summaries
Every issue of The New England journal of medicine moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.
Specialties
The New England journal of medicine covers research in these specialties.
Recent summaries
The latest articles summarized from The New England journal of medicine.
Assessing Multiple Treatment Regimens for Tuberculosis.
Nov 19, 2026
This phase 2 randomized trial (PARADIGM4TB) asked whether new four-drug regimens containing ganfeborole and/or BTZ-043 could shorten or improve tuberculosis treatment compared with the standard 24-week HRZE regimen, using early sputum culture clearance (log10 time-to-positivity slope) as the primary measure. Two regimens, ganfeborole-bedaquiline-pretomanid-moxifloxacin (BPMG) and BTZ-043-bedaquiline-delamanid-moxifloxacin (BDMT), showed a posterior probability of superiority over HRZE of 0.83 and 0.99, respectively, with acceptable safety profiles to advance to further evaluation. The results were used to select regimens for further study rather than to establish definitive efficacy.
Acute Respiratory Distress Syndrome.
Nov 18, 2026
This review by Calfee and McAuley summarizes the current understanding of acute respiratory distress syndrome (ARDS), a common cause of acute hypoxemic respiratory failure. It addresses the key management challenges, including treating the underlying trigger, avoiding ventilator-induced lung injury and volume overload, and resolving controversies around supporting nonintubated patients, personalizing positive end-expiratory pressure, using innovative ventilation strategies, and giving glucocorticoids. The authors also highlight whether precision medicine approaches based on biologic, radiographic, or physiologic subphenotypes can improve outcomes.
Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age.
Nov 16, 2026
This phase 3, double-blind, placebo-controlled trial asked whether once-weekly semaglutide could safely and effectively reduce body-mass index in children aged 6 to under 12 years with obesity, a group with few durable medical treatment options. Among 167 children randomized 2:1 to semaglutide or placebo alongside lifestyle counseling, semaglutide produced a mean BMI reduction of 13.5% versus a 2.7% increase with placebo at week 68 (between-group difference -16.2 percentage points). Gastrointestinal adverse events were more common with semaglutide, but led to discontinuation in only one participant in that group.
Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma.
Nov 11, 2026
This phase 3 randomized, double-blind trial asked whether adding intismeran autogene, an individualized neoantigen mRNA vaccine, to pembrolizumab improves outcomes after complete resection of high-risk stage IIB–IV melanoma compared with pembrolizumab alone. Among 1,137 patients, intismeran plus pembrolizumab significantly improved recurrence-free survival (24-month rate 82.2% vs. 70.0%) and distant-metastasis-free survival (88.5% vs. 80.2%), with benefit emerging after about 6 months and no early separation. Grade 3 or higher adverse events were modestly more common with the combination (23.6% vs. 20.3%), and treatment-related deaths were rare (8 patients, 1.1%).
Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.
Nov 11, 2026
This randomized comparative-effectiveness trial asked whether aspirin is noninferior to warfarin or rivaroxaban for preventing venous thromboembolism (VTE) and death after hip or knee arthroplasty. Among 15,317 patients analyzed, the 6-month composite of death or symptomatic VTE occurred in 1.26% with aspirin, 1.01% with warfarin, and 0.94% with rivaroxaban, and aspirin did not meet the noninferiority criterion for effectiveness. Warfarin and rivaroxaban also did not show noninferior safety compared with aspirin, as their rates of bleeding, wound reoperation, or myocardial infarction were numerically higher.
Preventing Malaria Infections and Moving toward Malaria Elimination.
Nov 11, 2026
This review asks how malaria prevention can be strengthened and how countries can move toward elimination, given stalled progress and constrained funding. The authors survey current and emerging tools, including next-generation insecticide-treated nets, seasonal malaria chemoprevention, RTS,S and R21 vaccines, and future options such as long-acting injectable chemoprevention, transmission-blocking drugs and vaccines, and monoclonal antibodies. They conclude that success will depend on locally tailored, integrated combinations of these interventions, supported by strong surveillance, regulatory capacity, and national leadership.
ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels.
Nov 9, 2026
This phase 2b randomized, placebo-controlled trial (TYDAL-TIMI 78, part A) asked whether inhibiting ANGPTL4 with the monoclonal antibody MAR001 lowers fasting triglyceride levels in adults with elevated triglycerides. Among 235 participants treated subcutaneously every 4 weeks for 24 weeks, MAR001 at 300, 450, or 900 mg reduced fasting triglycerides at week 12 by 39.1, 40.5, and 45.3 percentage points more than placebo (all P<0.001). The adverse event rate was lower in the MAR001 group (69%) than in the placebo group (78%).
Left Bundle-Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block.
Nov 9, 2026
In this international randomized trial of 685 patients with atrioventricular block, the authors asked whether left bundle-branch pacing (LBBP) improves clinical outcomes compared with right ventricular pacing (RVP). At a median follow-up of about 35 months, the composite of death, heart failure hospitalization, or pacing-induced cardiomyopathy occurred in 8.5% of LBBP patients versus 19.2% of RVP patients (HR 0.41), and the trial was stopped early at interim analysis. LBBP was therefore superior to RVP for this composite outcome, with serious non-procedural adverse events occurring at similar rates in both groups.
Community and EMS Interventions to Improve Survival in Cardiac Arrest.
Nov 9, 2026
This cluster-randomized trial in North Carolina asked whether a multifaceted community and EMS intervention (911 telecommunicator training for rapid cardiac arrest recognition and CPR instruction, community CPR training, and enhanced AED use before EMS arrival) would improve survival with good neurologic outcome after out-of-hospital cardiac arrest compared with usual care. The intervention did not improve the primary outcome: 9.0% of patients in the intervention group versus 9.4% in the usual-care group survived to discharge with a Cerebral Performance Category score of 1 or 2 (adjusted odds ratio 0.97; 95% CI, 0.75 to 1.26). The authors conclude that this community and EMS strategy did not produce better favorable neurologic outcomes than usual care.
Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity.
Nov 9, 2026
This study tested whether retatrutide, an investigational once-weekly GIP/GLP-1/glucagon receptor triple agonist, could relieve pain from knee osteoarthritis in adults with obesity across two phase 3 trials (TRIUMPH-4 and TRIUMPH-1-OA). Retatrutide produced significantly greater reductions in WOMAC pain scores and body weight than placebo at 68 and 80 weeks, with weight loss of roughly 20–24% in TRIUMPH-4. Serious adverse events were more common with retatrutide than placebo, and gastrointestinal events were the most frequent side effects.
